Pfizer's $PFE Gene Therapy Shows Positive Results in Hemophilia A Late-Stage Phase 3 Study

Jul 24, 2024, 10:49 AM

Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The therapy, developed in collaboration with Sangamo Therapeutics, aims to reduce bleeding episodes in patients with the severe bleeding disorder. The study's success marks a significant milestone in the treatment of Hemophilia A, offering hope for improved management of the condition. Pfizer's stock symbol is $PFE, and the therapy met its goal in a pivotal late-stage trial.